Overview

Immodulators, Volume 151 explores the pivotal role immodulators play in regulating immune responses for health and disease management. The book provides an in-depth overview of various classes of immunomodulatory agents, including biologics, small molecules, natural compounds, and synthetic drugs, examining their mechanisms of action and therapeutic applications. Chapters in this new release include Marine-Derived Polysaccharides and Peptides as Next-Generation Immunomodulators: Molecular Mechanisms, Therapeutic Potential, and Translational Challenges, Advances in Immunomodulation: From Dietary Influence to Computational Precision, iPSC-derived immunotherapy for Tau and Alzheimer's disease, and much more. Additional sections cover Antibodies targeting amyloid-β and Tau oligomers in Alzheimer's Disease, Biosimilars: Antibody and Nanobody Based Therapeutic Approaches Towards Protein Misfolding Diseases, Immunomodulator drugs: mechanisms of action and systemic effects, Microbiome and microbial products as immunomodulators: implication for gastrointestinal cancers, Integration of Network pharmacology, docking, and dynamics analysis to investigate the immunomodulatory activity of Pongamia pinnata, Transcriptomic Insights into Epigenetic and Immunomodulatory Roles of Nuclear Histone Genes in Bladder Cancer: A bioinformatics Approach, Utilizing DREIMT Database for Drug Prioritization in Immunomodulatory Therapy for Psoriasis and Psoriatic Arthritis, and many additional topics.

Full Product Details

9780443345210

Table of Contents

Reviews

Author Information

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Tab Content 6

Countries Available